

GENERAL MEETING OF APRIL 28, 2020

WRITTEN QUESTION

Written questions may be submitted to the Company, pursuant to the rules established by law, with respect to any General Meeting. In conformity with the legislation in force, an answer is deemed to have been given to a written question provided it has been displayed on the Company's website.

On April 19, 2020 the Board received the following question from Mr. Jacques BREYSSE:

*“In the current context of the coronavirus epidemic, there would appear to be a **manifest lack of potential antiviral treatments based upon chemical molecules.**”*

An article by Bernard MEUNIER in the current edition (May 2020) of Actualité Chimique is damning in this regard: “... on reading this list of antivirals, the absence of molecules developed in France or in other European countries is readily apparent...”

*A discussion of public policy with respect to government funded research is clearly not an appropriate subject for a general meeting of shareholders, but regarding non-government funded research, and recalling the numerous innovations in chemical treatments developed in the past by **RHONE-POULENC**, one of the original companies involved in the merger that created SANOFI.*

*Would it not appear to be an opportune moment for the Company to return to this traditional area of research and **as a matter of urgency relaunch a research program into chemical therapies?**”*

Response to the written question:

“Sanofi's research into small chemical molecules in the antiviral area occurred over 20 years ago and the Company no longer has any products in this class in our research and development portfolio.

*Sanofi's strategy, for numerous years, in the area of antivirals has been primarily based upon **prevention through our Vaccines business.** Since the beginning of the COVID-19 pandemic, Sanofi has mobilized its significant know-how in vaccine development – in particular its expertise in flu viruses, and its work on the virus responsible for severe acute respiratory syndrome (SARS) – to forge several collaborations that are studying various novel approaches to finding a sure and effective vaccine.*

*The Company's R&D portfolio includes **antivirals developed using biologic methods**, in particular a monoclonal antibody against human respiratory syncytial virus and a tri-specific monoclonal antibody against HIV.*

*The Company is also maintaining its commitment to the development of **treatments for infectious diseases** where the focus should be on **antibacterial agents**. In 2018, Evotec AG and Sanofi decided to accelerate R&D in this area by creating a new open innovation platform under Evotec's management based near Lyon. To support the creation of this platform, Sanofi licensed most of its infectious disease research and early-stage development portfolio and transferred its infectious disease research unit to Evotec. Recourse to external innovation constitutes an efficient model which permits the conduct of preclinical research through to a stage where Sanofi can decide whether to exercise an option to take over development.*

Sanofi's internal research portfolio currently includes five projects for antibacterial medicines or vaccines.”

* * *